The GenoDiabMar Registry: A Collaborative Research Platform of Type 2 Diabetes Patients.

It should be noted that the use of drugs with a demonstrated nephroprotective effect—such as sodium–glucose co-transporter inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP1-RA)—was practically anecdotal at the baseline visit (years 2012–2015); however, we observed a clear trend towards an increase in the prescription of these drugs at the final visit (V2).

also in 19,460 other papers